HC Wainwright Reiterates “Buy” Rating for Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ:DVAX)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They presently have a $29.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 162.92% from the stock’s previous close. HC Wainwright also issued estimates for Dynavax Technologies’ FY2026 earnings at $0.32 EPS.

Separately, The Goldman Sachs Group reduced their price objective on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $23.67.

Dynavax Technologies Stock Up 2.5 %

Dynavax Technologies stock opened at $11.03 on Tuesday. Dynavax Technologies has a fifty-two week low of $9.74 and a fifty-two week high of $15.15. The company has a debt-to-equity ratio of 0.35, a quick ratio of 13.18 and a current ratio of 14.18. The company has a market capitalization of $1.44 billion, a P/E ratio of 183.83 and a beta of 1.37. The stock has a 50-day simple moving average of $11.05 and a 200-day simple moving average of $11.28.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.02. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. The business had revenue of $73.80 million during the quarter, compared to the consensus estimate of $76.92 million. During the same period in the previous year, the business earned $0.03 EPS. Equities research analysts expect that Dynavax Technologies will post 0.16 earnings per share for the current year.

Institutional Trading of Dynavax Technologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Congress Asset Management Co. MA raised its stake in shares of Dynavax Technologies by 0.4% during the 4th quarter. Congress Asset Management Co. MA now owns 227,135 shares of the biopharmaceutical company’s stock worth $3,175,000 after buying an additional 799 shares in the last quarter. Diversified Trust Co raised its stake in shares of Dynavax Technologies by 3.2% during the 1st quarter. Diversified Trust Co now owns 29,548 shares of the biopharmaceutical company’s stock worth $367,000 after buying an additional 925 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Dynavax Technologies by 1.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 1,172 shares in the last quarter. SummerHaven Investment Management LLC raised its stake in shares of Dynavax Technologies by 2.4% during the 2nd quarter. SummerHaven Investment Management LLC now owns 54,926 shares of the biopharmaceutical company’s stock worth $617,000 after buying an additional 1,303 shares in the last quarter. Finally, Texas Permanent School Fund Corp raised its stake in shares of Dynavax Technologies by 1.3% during the 1st quarter. Texas Permanent School Fund Corp now owns 113,128 shares of the biopharmaceutical company’s stock worth $1,404,000 after buying an additional 1,467 shares in the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.